[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Bulletin du Cancer

• Publication date

  2020-04-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bulcan.2020.02.010PMID 32252973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

  2020cited by this paper
• Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

  2019cited by this paper
• Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide‐ and lenalidomide‐containing regimens

  2019cited by this paper
• 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

  2019cited by this paper
• Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.

  2019cited by this paper
• Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions.

  2018cited by this paper
• Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis

  2018cited by this paper
• Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

  2018cited by this paper
• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

  2018cited by this paper
• Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians

  2018cited by this paper
• Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

  2018cited by this paper
• Pharmacokinetic drug interactions of the non‐vitamin K antagonist oral anticoagulants (NOACs)

  2018cited by this paper
• Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

  2018cited by this paper
• Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences.

  2018cited by this paper
• Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.

  2018cited by this paper
• Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin

  2017cited by this paper
• Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation

  2017cited by this paper
• Continuation of low‐molecular‐weight heparin treatment for cancer‐related venous thromboembolism: a prospective cohort study in daily clinical practice

  2017cited by this paper
• The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation

  2017cited by this paper
• Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation

  2017cited by this paper
• Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study

  2016cited by this paper
• Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib

  2014cited by this paper
• An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function

  2014cited by this paper
• Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.

  2013cited by this paper
• Edoxaban versus warfarin in patients with atrial fibrillation.

  2013cited by this paper
• Pharmacokinetic and Pharmacodynamic Drug Interactions With New Oral Anticoagulants

  2013cited by this paper
• Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

  2011cited by this paper
• Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

  2006cited by this paper

• Évaluation pharmaceutique des risques de prescription des anticoagulants oraux directs chez le patient atteint de cancer

  2024cites this paper
• [Prophylaxis and management of cancer-associated thrombosis: Practical issues about anticoagulant use].

  2022cites this paper